400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
2021-05-20
FDA-2014-N-1130
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
This guidance document provides recommendations for nonclinical testing and study design considerations for Investigational Device Exemptions (IDEs) feasibility and pivotal clinical studies for implanted Brain-Computer Interface (BCI) devices for patients with paralysis or amputation. The field of implanted BCI devices is progressing rapidly from fundamental neuroscience discoveries to translational applications and market access. Implanted BCI devices have the potential to bring benefit to people with severe disabilities by increasing their ability to interact with their environment, and consequently, providing new independence in daily life. For the purposes of this guidance document, implanted BCI devices are neuroprostheses that interface with the central or peripheral nervous system to restore lost motor and/or sensory capabilities in patients with paralysis or amputation.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2014-N-1130.
摩熵医械2025-11-28
摩熵医械2025-11-17
赛柏蓝2025-11-14
摩熵医械2025-11-12
赛柏蓝2025-11-12
CHC医疗传媒2025-10-30
赛柏蓝2025-10-29
赛柏蓝2025-10-28
赛柏蓝2025-10-24
赛柏蓝2025-10-24
2025-12-01
2025-11-27
2025-11-26
2025-11-24
2025-11-24
2025-11-21
2025-11-18
2025-11-18
2025-11-17
2025-11-13
2025-11-13
2025-11-13
2025-11-11
2025-11-11
2025-11-11
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2025-11-17
2025-09-17
2025-09-17
2025-09-17
2025-07-21
2025-02-05
2025-01-31
2025-01-31
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07